强化瑞苏伐他汀治疗对急性冠脉综合征患者高敏C反应蛋白及血脂的影响

摘要

Objective To investigate the influence of augmentation rosuvastatin treatment early on the serum lipid and high sensitive reactive protein C (hs-CRP)in patients with acute coronary syndrome and its safely. Methods 92 patients were divided into two groups randomly: rosuvastatin control group(group A, rosuvastatin was 10 mg/d based routiae therapy) and augmentation rosuvastatin group (group B, rosuvastatin was 40 mg/d based routine therapy). The therapeutic time was 4 weeks. Serum total cholesterol (TC), low density lipoprotein- cholesterol (LDL-C) and hs-CRP contents were measured before and after therapy. Results After therapy, the serum lipid and hs-CRP levels all significantly decreased in two groups (P＜0.05). But compared with group A, the hs-CRP, TC and LDL-C were more decreased (P＜0.05 all) in group B. There were no serious harmful event in two groups.Conclusion Augmentation rosuvastatin treament may more decrease hs-CRP and serum lipid levels, with more safety.%目的 观察不同剂量瑞苏伐他汀(10mg/d和40mg/d)早期干预对急性冠脉综合征(ACS)患者高敏C反应蛋白(hs-CRP)、血脂中总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)水平的影响,以了解较大剂量瑞苏伐他汀对ACS患者炎症抑制的影响及安全性.方法 将92例ACS患者被随机分为两组,A组47例,在常规治疗基础上口服瑞苏伐他汀10 mg/d,睡前服用;B组45例,在常规治疗基础上口服瑞苏伐他汀40 mg/d,睡前服用.两组均在入院48 h内开始用药,治疗4周.于治疗前、后分别监测血清hs-CRP、血脂(TC、LDL-C)浓度,同时观察用药的安全性.结果 治疗后两组患者血清hs-CRP浓度、TC、LDL-C均有不同程度的下降(P＜0.05),与A组相比较,B组hs-CRP、TC、LDL-C下降更明显(P均＜0.05).两组均未发生严重不良反应事件.结论 早期应用较大剂量瑞苏伐他汀治疗可显著降低急性冠脉综合征患者血清高敏C反应蛋白浓度及总胆固醇、低密度脂蛋白胆固醇水平,并具有良好的安全性.